From:  Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques

Represents FXR agonist drugs for the MASLD/MASH under clinical trial phase II/III trails

Primary mechanismAgent (trial name)StructureClinical trialsNCT number
(clinicaltrials.gov)		Reference
FXR agonist and a chemokine receptor type 2/5 antagonistLJN452 and CVC (cenicriviroc) + Phase 2bNCT03517540[174, 175]
FXR agonistCilofexor (GS-9674)Phase 2NCT02854605[176]
FXR agonist and statinObeticholic acid and atorvastatin + Phase 2NCT02633956[177]
Non bile acid FXR agonistHPG1860
Phase 2aNCT05338034[178]
FXR agonistCS0159
Phase 2NCT05591079[179]
FXR agonistObeticholic acidPhase 3NCT03439254[180]
FXR agonistEYP001a (vonafexor)
Phase 2NCT03812029[181]
FXR agonist EDP-305
Phase 2NCT03421431[182]
Tricyclic FXR agonist HEC96719
Phase 2NCT05397379[183]
Non-steroidal FXR agonistPX-104
Phase 2NCT01999101[184]
Return to article view

FXR: farnesoid X receptor; MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis